Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
USD 13.75
(-2.2%)
USD 13.75
(-2.2%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 50 Million | - | - |
| Cost of Revenue | 195 Thousand | 329 Thousand | - |
| Gross Profit | 49.8 Million | -329 Thousand | - |
| Operating Expenses | 33.72 Million | 22.39 Million | 28.64 Million |
| Selling, General and Administrative Expenses | 6.12 Million | 5.49 Million | 6.28 Million |
| Research and Development Expenses | 27.6 Million | 16.89 Million | 22.36 Million |
| Other Expenses | - | -92 Thousand | -91 Thousand |
| Cost and Expenses | 33.92 Million | 22.72 Million | 28.64 Million |
| Operating Income | 16.07 Million | -22.72 Million | -28.64 Million |
| Interest Expense | 208 Thousand | 388 Thousand | 332 Thousand |
| Income Tax Expense | 450 Thousand | - | 241 Thousand |
| Earnings before Tax | 23.17 Million | -24.25 Million | -29 Million |
| Net Income | 22.72 Million | -24.25 Million | -29 Million |
| Earnings Per Share Basic | 1.36 | -0.97 | -1.74 |
| Earnings Per Share Diluted | 1.28 | -0.97 | -1.63 |
| Weighted Average Shares Outstanding | 16.67 Million | 25.13 Million | 16.67 Million |
| Weighted Average Shares Outstanding (Diluted) | 17.76 Million | 25.13 Million | 17.76 Million |
| Gross Margin | 1.00 | - | - |
| EBIT Margin | 0.47 | - | - |
| Profit Margin | 0.45 | - | - |
| EBITDA | 23.57 Million | -23.53 Million | -28.33 Million |
| Earnings Before Tax Margin | 0.32 | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 50 Million | - | 50 Million |
| Cost of Revenue | 60 Thousand | 61 Thousand | 37 Thousand | 195 Thousand | - | 42 Thousand |
| Gross Profit | -60 Thousand | -61 Thousand | -37 Thousand | 49.8 Million | - | 49.95 Million |
| Operating Expenses | 10.88 Million | 9.86 Million | 9.63 Million | 33.72 Million | 8.06 Million | 11.02 Million |
| Selling, General and Administrative Expenses | 2.98 Million | 2.09 Million | 1.62 Million | - | 1.57 Million | 1.56 Million |
| Research and Development Expenses | 7.9 Million | 7.77 Million | 8.01 Million | - | 6.49 Million | 9.46 Million |
| Other Expenses | -77 Thousand | -6000.00 | -47 Thousand | -177 Thousand | -36 Thousand | -76 Thousand |
| Cost and Expenses | 10.94 Million | 9.93 Million | 9.67 Million | 33.92 Million | 8.06 Million | 11.06 Million |
| Operating Income | -10.94 Million | -9.93 Million | -9.67 Million | 16.07 Million | -8.06 Million | 38.93 Million |
| Interest Expense | - | - | - | 208 Thousand | - | 116 Thousand |
| Income Tax Expense | - | - | -161 Thousand | 450 Thousand | -118 Thousand | 729 Thousand |
| Earnings before Tax | -9 Million | -8.41 Million | -7.93 Million | 23.17 Million | -6.36 Million | 42.29 Million |
| Net Income | -9 Million | -8.41 Million | -7.76 Million | 22.72 Million | -6.25 Million | 41.56 Million |
| Earnings Per Share Basic | -0.35 | -0.33 | -0.31 | - | -0.25 | 1.62 |
| Earnings Per Share Diluted | -0.35 | -0.33 | -0.31 | - | -0.25 | 1.62 |
| Weighted Average Shares Outstanding | 25.72 Million | 25.72 Million | 25.13 Million | 25.13 Million | 25.42 Million | 25.72 Million |
| Weighted Average Shares Outstanding (Diluted) | 25.72 Million | 25.72 Million | 25.13 Million | 25.13 Million | 25.42 Million | 25.72 Million |
| Gross Margin | - | - | - | 1.00 | - | 1.00 |
| EBIT Margin | - | - | - | - | - | 0.78 |
| Profit Margin | - | - | - | 0.45 | - | 0.83 |
| EBITDA | -10.88 Million | -9.86 Million | -9.63 Million | - | -6.32 Million | 38.97 Million |
| Earnings Before Tax Margin | - | - | - | 0.32 | - | 0.78 |
7030
RAM
TRV
5753
0HJO
BKEAY